Dr Lal PathLabs

November 12, 2021

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref.: Our earlier intimation dated October 26, 2021 w.r.t. acquisition of 100% stake in Suburban Diagnostics (India) Private Limited

Dear Sir/Madam,

With reference to the captioned subject and in continuation to our earlier intimation dated October 26, 2021 w.r.t. acquisition of 100% stake in Suburban Diagnostics (India) Private Limited and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that Dr. Lal PathLabs Limited ("the Company") has completed the said acquisition on November 12, 2021 as per the terms and conditions of the Share Purchase Agreement.

Pursuant to completion of said acquisition, Suburban has now become Wholly-owned Subsidiary of the Company.

We request you to please take the same on record.

Thanking You,

For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head